Pre-interventional statin medication shows a benefit in carotid artery stenosis patients treated with endarterectomy; however, there are few data available on patients treated with stent-angioplasty. This study shows that pre-interventional statin medication has a significant protective effect against peri-interventional stroke, myocardial infarction, or death (composite endpoint) in patients with internal carotid artery stenosis treated with stent-angioplasty. Accordingly, statins could be considered as a standard pre-interventional medical therapy in connection with carotid stenting.
BACKGROUND AND PURPOSE
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are part of the best available medical treatment for patients with atherosclerotic stenosis, and reduce the incidence of stroke and myocardial infarction. 1e5 The antiatherosclerotic effect of statins not only correlates with the decrease in low-density lipoprotein (LDL) cholesterol, but they also have beneficial pleiotropic effects beyond their hypolipidemic action. 6 In patients with atherosclerotic stenoses treated by carotid endarterectomy (CEA) or percutaneous coronary intervention, the peri-procedural risk of stroke, myocardial infarction, and death is lowered by preprocedural treatment with statins.
7e9 Relevant mechanisms may be effects on platelet adhesion, reduction of thrombosis, improved endothelial cell function, upregulation of endothelial nitric oxide synthase, plaque stability, decreased vascular smooth muscle cell proliferation and migration, and neuroprotection and modulation of inflammation.
10e20 Stent-angioplasty is increasingly used as an alternative therapy to CEA in treating stenoses of arteries supplying the brain. Stent-angioplasty induced effects such as platelet activation, thrombosis, and inflammatory processes within the vessel wall appear to be attenuated by statins. 21, 22 Accordingly, peri-interventional risk reduction in stenting is an essential issue, and the benefit of statin use before stenting has to be evaluated, not least because little evidence is available currently for peri-procedural drug therapy in carotid artery stenting. 23 The aim of this study was to investigate the effect of pre-procedural statin medication on the risk of peri-procedural stroke, myocardial infarction, and mortality in a set of patients at a specialized center treated with stent-angioplasty for extracranial carotid stenoses.
METHODS
The study included all patients treated for the first time with stent-angioplasty for internal carotid artery stenosis from 1/2002 to 9/2012. Data were consecutively collected in a database of all patients with extracranial and intracranial stenosis treated with stent-angioplasty at the authors' stroke center. Procedures involving intracranial vessels and the stenting of recurrent stenosis in the same patient were excluded. To achieve a homogenous group of patients for this study, stenting of other extracranial vessels such as the common carotid, subclavian, vertebral, or brachiocephalic trunk, was excluded from the analysis.
Indication for treatment (asymptomatic stenosis, transient monocular blindness, TIA, minor stroke or major stroke) as well as patients' pre-treatment condition including risk factors (arterial hypertension, diabetes mellitus, hyperlipidemia, nicotine abuse, coronary artery disease), lipometabolism parameters, medication (including statin and dose), time span between neurological symptoms and stenting in symptomatic patients, and details of procedure (including type of stent) were documented. All variables in the database were defined prospectively.
At the authors' center, patients with moderate to severe (>70% ECST ¼ >50% NASCET ) carotid artery stenosis are treated invasively if this stenosis had caused neurological symptoms within the previous 6 months or e in asymptomatic patients e if there are indications for an increased risk of stroke (e.g. rapidly progressive stenosis, microemboli). 24 Some patients with asymptomatic stenosis were treated within the SPACE-2-study. Patients are treated with stenting instead of endarterectomy if a) the stenosis is not accessible to vascular surgery, b) there is increased perioperative risk, c) in case of pre-treatment by vascular surgery or following radiotherapy, d) within a randomized clinical trial, e) in accordance with patient preference, and f) in combination with intracranial thrombectomy in acute stroke patients. Exclusion criteria for stenting were stenosis inaccessibility as a result of aortic arch anatomy or severe atherosclerosis, severe renal insufficiency (creatinine >2.0 mg/dL, glomerular filtration rate <30 mL/min), and severe allergies to aspirin, clopidogrel, or contrast media (anaphylactic reactions). Stenosis assessment at baseline (degree of stenosis and characteristics) was performed by duplex ultrasound, optionally supplemented with contrastenhanced CT/MRI or digital subtraction angiography. Ultrasound stenosis graduation was performed in accordance with DEGUM ultrasound criteria for grading internal carotid artery stenoses. 25 During the stenting procedure, the degree of stenosis was re-evaluated angiographically, and treatment was undertaken only if moderate to severe stenosis was confirmed.
All patients were premedicated with ASA 100 mg and clopidogrel 75 mg for at least 3 days prior to stenting. Alternatively for clopidogrel, a loading dose of 300e600 mg was administered 1 day prior to stent-angioplasty. Acute ischemic stroke patients undergoing emergency stenting were treated with tirofiban in the first 12 hours after intervention. Subsequently, loading doses of ASA and clopidogrel were administered. Prior to stenting, all patients gave informed consent. All stenting procedures were performed by experienced interventional neuroradiologists. Stenting was performed without cerebral protection devices (CPD). After stenting all patients were monitored at the stroke unit, undergoing examinations every 6 hours by experienced stroke physicians. Patients with new clinical symptoms during or post-intervention were re-evaluated with CT or MRI to establish whether a new ischemic stroke or an intracranial hemorrhage had occurred.
Definitions
Symptomatic artery stenosis was defined as neurological symptoms associated with stenosis lasting 24 hours (TIA) or longer (stroke) within the 6 months prior to stenting. TIA was defined as any neurological deficit (including transient monocular blindness) lasting no longer than 24 hours. Any neurological deficit persisting for longer than 24 hours and increasing the NIHSS by 4 points or less was classified as a minor stroke, whereas any neurological deficit persisting for longer than 30 days and related to an increase of NIHSS by more than 4 points was classified as a major stroke. A myocardial infarction was defined by a rise in cardiac biomarkers (preferably troponin) by at least one value above the 99th percentile of the upper reference limit and evidence of myocardial ischemia with at least one symptom of ischemia (ECG changes indicative of new ischemia, new ST/T changes or new left-bundle branch block, new onset of pathological Q-waves in ECG, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality).
Complications and endpoints
Complications after stent-angioplasty, such as TIA, stroke, myocardial infarction prior to discharge, or death were analyzed with regard to pre-interventional statin medication. In the case of death, the most likely reason was also documented. Affecting mostly the long-term outcome, primary endpoint was defined as a composite of the main severe risks in patients with systemic atherosclerosis: ischemic stroke, myocardial infarction, and death. As a secondary endpoint a composite of ischemic stroke and death was defined. Because the combination of ASA and clopidogrel before stenting, tirofiban in emergency stenting, and vulnerable brain tissue elevate intracranial bleeding complication risks, composite secondary endpoints were intracranial bleeding and stroke, and stroke, intracranial bleeding, and death. Details of cases of intracranial bleeding were recorded (side, localization, reason).
Statistics
Univariate analysis was performed on patients with preprocedural statins compared with patients with no statins before the stenting procedure. Statistical testing methods were ManneWhitney U test, chi-square test, and odds ratio with 95% confidence intervals. When expected cell frequency was <5, the Fisher Exact test was used. Adjustment for confounding factors was performed by multivariate logistic regression analysis for all endpoints. The multivariate analysis encompassed the independent variables age, sex, arterial hypertension, diabetes, smoker, hypercholesterolemia, statin medication, coronary heart disease, and tirofiban medication in a stepwise logistic regression model. Any p values larger than .10 were removed. To strengthen multivariate analysis, only those indications for therapy or laboratory values significantly correlated (p .05) with any endpoint in univariate analysis were used in the multivariate logistic regression model. Statistical analysis was performed using STATA-IC 12.
The study was approved by the local ethics committee.
RESULTS
Consecutive patients (344) with moderate to high-grade stenosis of the internal carotid artery and treated with stent-angioplasty were selected from the database. The majority of patients were male (76%), and the median age was 70 years (p25: 63; p75: 76 years). Most patients had high-grade stenosis (median 87.5% ECST; p25: 80%; p75 90%). In 20%, the indication for interventional therapy was asymptomatic stenosis, and in 80% symptomatic stenosis (mainly TIA and minor stroke). The main vascular risk factors were arterial hypertension (85%), hypercholesterolemia (67%), coronary artery disease (39%), diabetes mellitus (28%), and smoking (24%). Prior to the stenting procedure, 72% of the patients were on antihypertensives, and 60% were on statins. 49% were treated within 7 days of symptom onset, 7% had emergency stenting (<24 hours after symptom onset) (for further details, see Table 1 ). For details of statin medication and stents used, see Tables S1 and S2  (supplementary material) . Of patients on statin medication, 91% had hypercholesterolemia, whereas 9% received statins because of atherosclerotic changes in the coronary/carotid arteries. Of the patients without statins, 30% had hypercholesterolemia, 95% of these were stented in emergency situations involving symptomatic stenosis. In logistic regression analysis there was no significant effect of cholesterol, LDL-cholesterol, or triglycerides on any endpoint.
Lipid parameters

Tirofiban
Patients treated with tirofiban (n ¼ 19) because of emergency stenting had significantly more intracerebral bleeding complications (n ¼ 4; p ¼ .000) and non-significantly subarachnoid hemorrhage (n ¼ 1; p ¼ .108). All of these patients had undergone successful stenting. Two patients (0.6%) had tirofiban without ASA or clopidogrel before stenting. These patients had a significantly elevated bleeding risk but no significantly elevated ischemic stroke risk (for details see Table S3 , supplementary material).
Intracerebral bleeding complications
All non-fatal intracranial bleeds (n ¼ 7) were ipsilateral. Two of these were space occupying with ventricular hemorrhage, one was related to hyperperfusion syndrome, two patients had hemorrhage in the infarct area, and two patients had subarachnoid hemorrhage. Age and sex did not differ significantly between the patient groups treated with or without statins. In the statin group, vascular risk factors were more frequent. There was a significant difference for arterial hypertension, hypercholesterolemia, coronary artery disease, cholesterol, and LDL-cholesterol. No significant difference was found for severity or side of stenosis. Significantly more patients with statins had asymptomatic stenosis and minor strokes, whereas fewer had stroke as an indication for stenting (for details, see Table 2 ). 
Peri-procedural complications
Nineteen patients (5.5%) had a peri-interventional TIA, 28 (8.1%) had ischemic strokes (22 ipsilateral, 6 bilateral, 0 only contralateral), one (0.3%) had a myocardial infarction, and four (1.2%) patients died. Patients with statins had fewer ischemic strokes, less subarachnoid hemorrhage, less myocardial infarction, and fewer fatal outcomes, although the differences were not significant (for details see Table 3 ). In univariate analysis, no indication for stenting or any laboratory value was significantly (p .05) correlated with any endpoint (data not shown), thus no indication for stenting or any laboratory value was included in multivariate analysis. Analyzing patients with asymptomatic versus symptomatic stenosis showed no significant difference regarding peri-procedural stroke, TIA, myocardial infarction, or death. The median time between neurological symptoms and stenting in symptomatic patients was 10 days (p25: 5, p75: 20) and did not significantly correlate with any endpoint. Thirty-six patients received a clopidogrel loading dose 300 mg before stenting. In univariate analysis there was no significant correlation with any endpoint. Also, no stent type had a significant correlation with any endpoint in univariate analysis. Primary endpoint events occurred in 33 patients (9.6%). After adjustment for age, sex, tirofiban medication, and risk factors, statin medication before stenting remained the only independent variable with a significant protective effect related to the primary endpoints of ischemic stroke, myocardial infarction (MI), and death (OR 0.31, p ¼ .006) and the secondary endpoints ischemic stroke and MI (OR 0.20, p ¼ .002), ischemic stroke and intracranial hemorrhage (OR 0.38, p ¼ .024), and ischemic stroke, intracranial hemorrhage, and death (OR 0.37, p ¼ .016). Coronary heart disease was a non-significant risk factor for primary endpoint and all secondary endpoints. Tirofiban was significantly correlated with elevated bleeding risk in secondary endpoint ischemic stroke and ICH (OR 4.35, p ¼ .026) and secondary endpoint ischemic stroke, ICH, and death (OR 5.57, p ¼ .006). Hypercholesterolemia was a nonsignificant risk factor for secondary endpoint ischemic stroke or MI (for details, see Table 4 ).
DISCUSSION
Statin use prior to stent-angioplasty showed a significant preventive effect both for the primary endpoint as a combination of peri-interventional ischemic stroke, myocardial infarction, and death, and for secondary endpoints including intracranial hemorrhage and mortality. It needs to be noted, however, that the baseline characteristics differed significantly in both groups. On the one hand, patients in the statin group displayed significantly higher vascular risk factors and co-morbidities that may have increased their risk of stroke, MI, or death. On the other hand, these patients may have profited from regular medical examinations and better medical prevention regimes. Furthermore, in the statin group stent-angioplasty was more frequently performed in cases of asymptomatic stenosis. Assuming a higher interventional risk level for stentangioplasty for symptomatic stenosis, this baseline imbalance may be relevant. Nonetheless, multivariate analysis including all these factors confirmed the role of statin medication as a significant protective factor against periinterventional complications in carotid stenting. Although statin use was reported to be related to increased risk of cerebral hemorrhage, 26 increased rates of clinically relevant post-procedural intracranial bleeding were not observed in the statin group. This observation is supported by the finding that statin use does not correlate with higher mortality or intracranial bleeding rates in patients with acute ischemic stroke even if they have undergone thrombolytic therapy. 27 Patients having emergency stenting procedures because of acute ischemic stroke and without premedication with platelet inhibitors received tirofiban and had a higher risk of intracranial bleeding complications. In all of these patients recanalization was achieved.
The results of the study are similar to the known risk reducing effect of statin therapy in patients undergoing carotid endarterectomy, 7, 8 and are congruent with the data published regarding the relationship between risk reduction in stenting and pre-interventional statin medication. 28e30 In both CEA and stent-angioplasty, statins appear to prevent embolic complications through their pleiotropic effects such as plaque stabilization and the reduction of intravascular thrombosis. Prevention of embolic events is an important issue, especially in carotid artery stenting as it has been shown to generate more cerebrovascular lesions than CEA. 31 The preventive effect of statins is corroborated by studies showing statin use being associated with reduced plaque volume and atheroma regression in the carotid circulation, 32 as well as less embolic debris during carotid artery stenting. 33 That there are higher rates of periinterventional strokes in this study in comparison with previously published data 28 may be associated with the much higher percentage of symptomatic patients in this analysis. The present study population reflects the medical routine at a specialized stroke center, including high risk patients with multiple morbidity sent from surrounding hospitals for emergency treatment. The peri-procedural complication rate correlates with the 9.4% risk of stroke or death (not including MI) in patients undergoing CAS within 7 days from the qualifying event. 34 In comparison with the published data of symptomatic patients only, 29 the present study had a similar complication rate, confirming the protective benefit of pre-interventional statin medication for the larger group of patients in this investigation. To achieve generalization of these results for all patients treated with stent-angioplasty, both symptomatic and asymptomatic patients were included in the analysis. Furthermore, patients with clinically asymptomatic stenoses may also have plaque instability, and these patients will benefit from statin treatment. In this study, statins showed LDL-cholesterol lowering effects; however, considering the impact of other multiple pleiotropic effects caused by statins, such as effects on endothelial function, inflammation, arterial myocyte proliferation, migration and apoptosis, plaque stability, platelet activity, and the coagulation process, the lowering of LDL-cholesterol is not the only relevant parameter for the achievement of successful risk reduction. 11, 35 As in other studies, LDL-cholesterol levels did not show a significant effect on any endpoint. Results of various studies suggest that treatment with statins should be indicated in accordance with the global vascular risk profile and not primarily on base-level LDLcholesterol concentrations. 36, 37 The limitations of this study are the retrospective analysis of prospectively collected data with lower impact than randomized comparison. The potentially protective effects of the long term use of statins prior to stent-angioplasty remain elusive, because the precise duration of their use before the stenting procedure was not documented prospectively and thus could not be included in this analysis. Plaque morphology as an important co-factor of peri-interventional stroke risk was not stringently documented and, therefore, could not be included in statistical analysis. As stent-angioplasty is frequently performed with CDP, CAS treatment without CPD in this study is another limit. Thus a direct transfer of the present results to patients treated with CPD may be restricted. However, placement of CPD systems is also suspected to cause embolic brain lesions. So statin associated plaque stabilization would be beneficial when using CPD too. With reference to potential gender specific effects of statins, the small proportion of female patients in this study is another limitation.
In summary, the present study demonstrates that the reduction of the risk of peri-interventional stroke, MI, and death in stent-angioplasty patients receiving statin premedication is similar to the peri-procedural risk reduction in patients treated with endarterectomy. These results are congruent with other published data and provide an opportunity not only to reduce the side effects of treatment but also to cut down on hospitalization rates and costs. 38 Hence statins should be part of best practice preinterventional medical treatment for atherosclerotic stenoses of arteries supplying the brain, not only in connection with endarterectomy but also with stent-angioplasty.
Conclusion
Pre-interventional statin medication significantly reduced the risk of stroke, myocardial infarction, or death following stent-angioplasty of the carotid arteries. Comparable with the therapy regimen for carotid endarterectomy, pretreatment with statins appears to be effective in reducing peri-interventional complications in patients treated with stent-angioplasty.
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